# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Canaccord Genuity analyst Kyle Mikson maintains Exact Sciences (NASDAQ:EXAS) with a Buy and maintains $75 price target.
Piper Sandler analyst David Westenberg maintains Exact Sciences (NASDAQ:EXAS) with a Overweight and raises the price target ...
- Baird Global Healthcare Conference
- Conference
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company m...
Wells Fargo analyst Brandon Couillard initiates coverage on Exact Sciences (NASDAQ:EXAS) with a Overweight rating and announ...
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the first...